Common alleles of predisposition in endocrine neoplasia

Current Opinion in Genetics and Development

Volumn 20, Issue 3, 2010, Pages 251-256

  Eng, Charis ^a,b  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; PROTEIN TYROSINE KINASE; PROTEIN RET; RET PROTEIN, HUMAN;

ALLELE; CANCER GENETICS; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC RISK; GERM LINE; HUMAN; HYPOPHYSIS ADENOMA; MULTIPLE ENDOCRINE NEOPLASIA; PENETRANCE; PRIORITY JOURNAL; PROTO ONCOGENE; REVIEW; RISK ASSESSMENT; THYROID MEDULLARY CARCINOMA; ENDOCRINE TUMOR; GENETICS; MEDULLARY CARCINOMA; THYROID TUMOR;

ALLELES; CARCINOMA, MEDULLARY; ENDOCRINE GLAND NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA; PENETRANCE; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS;

EID: 77953686253     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gde.2010.02.004     Document Type: Review

References (50)

1. Zbuk K., Eng C. Cancer phenomics: RET and PTEN as illustrative models. Nat Rev Cancer 2007, 7:35-45.
2. Mulligan L.M., Kwok J.B.J., Healey C.S., Elsdon M.J., Eng C., Gardner E., Love D.R., Mole S.E., Moore J.K., Papi L., et al. Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993, 363:458-460.
3. Mulligan L.M., Eng C., Healey C.S., Clayton D., Kwok J.B.J., Gardner E., Ponder M.A., Frilling A., Jackson C.E., Lehnert H., et al. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet 1994, 6:70-74.
4. Eng C., Clayton D., Schuffenecker I., Lenoir G., Cote G., Gagel R.F., Ploos van Amstel H.K., Lips C.J.M., Nishisho I., Takai S.-I., et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: International RET Mutation Consortium analysis. J Am Med Assoc 1996, 276:1575-1579.
5. Kloos R.T., Eng C., Evans D.B., Francis G.L., Gagel R., Gharib H., Moley J.F., Pacini F., Ringel M.D., Schlumberger M., Wells S.A. Medullary thyroid carcinoma: Management Guidelines of the American Thyroid Association. Thyroid 2009, 19:565-612.
6. Maher E.R., Eng C. The pressure rises: update on the genetics of phaeochromocytoma. Hum Mol Genet 2002, 11:2347-2354.
7. Hofstra R.M.W., Landsvater R.M., Ceccherini I., Stulp R.P., Stelwagen T., Luo Y., Pasini B., Höppener J.W.M., Ploos van Amstel H.K., Romeo G., et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994, 367:375-376.
8. Eng C., Smith D.P., Mulligan L.M., Nagai M.A., Healey C.S., Ponder M.A., Gardner E., Scheumann G.F.W., Jackson C.E., Tunnacliffe A., Ponder B.A.J. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet 1994, 3:237-241.
9. Gimm O., Marsh D.J., Andrew S.D., Frilling A., Dahia P.L.M., Mulligan L.M., Zajak J.D., Robinson B.G., Eng C. Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation. J Clin Endocrinol Metab 1997, 82:3902-3904.
10. Berndt I., Reuter M., Saller B., Frank-Raue K., Groth P., Grussendorf M., Raue F., Ritter M.M., Höppner W. A new hotspot for mutations in the RET proto-oncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia. J Clin Endocrinol Metab 1998, 83:770-774.
11. Gimm O., Niederle B.E., Weber T., Bockhorn M., Uktar J., Brauckhoff M., Thanh P.N., Frilling A., Klar E., Niederle B., Dralle H. RET proto-oncogene mutations affecting codon 790/791: a mild form of multiple endocrine neoplasia type 2A syndrome. Surgery 2002, 132:952-959.
12. Erlic Z., Hoffmann M.M., Sullivan M., Franke G., Peczkowska M., Harsch I., Schott M., Gabbert H.E., Valimaki M., Preuss S.F., et al. Pathogenicity of DNA variants and double mutations in multiple endocrine neoplasia type 2 and von Hippel-Lindau disease. J Clin Endocrinol Metab 2010, 95:308-313.
13. Lyonnet S., Bolino A., Pelet A., Abel L., Nihoul-Fekété C., Briard M.L., Mok-Siu V., Kaariainen H., Martucciello G., Lerone M., et al. A gene for Hirschsprung disease maps to the proximal long arm of chromosome 10. Nat Genet 1993, 4:346-350.
14. Angrist M., Bolk S., Thiel B., Puffenberger E.G., Hofstra R.M., Buys C.H.C.M., Cass D.T., Chakravarti A. Mutation analysis of the RET receptor tyrosine kinase in Hirschsprung disease. Hum Mol Genet 1995, 4:821-830.
15. Amiel J., Sproat-Emison E., Garcia-Barcelo M., Lantieri F., Burzynski G., Borrego S., Pelet A., Arnold S., Miao X., Griseri P., et al. Hirschsprung disease, associated syndromes and genetics: a review. J Med Genet 2008, 45:1-14.
16. Edery P., Lyonnet S., Mulligan L.M., Pelet A., Dow E., Abel L., Holder S., Nihoul-Fekété C., Ponder B.A.J., Munnich A. Mutations of the RET proto-oncogene in Hirschsprung's disease. Nature 1994, 367:378-380.
17. Romeo G., Ronchetto P., Luo Y., Barone V., Seri M., Ceccherini I., Pasini B., Bocciardi R., Lerone M., Kääriäinen H., Martucciello G. Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease. Nature 1994, 367:377-378.
18. Attié T., Pelet A., Sarda P., Eng C., Edery P., Mulligan L.M., Ponder B.A.J., Munnich A., Lyonnet S. A 7bp deletion of the RET proto-oncogene in familial Hirschsprung's disease. Hum Mol Genet 1994, 3:1439-1440.
19. Mulligan L.M., Eng C., Attié T., Lyonnet S., Marsh D.J., Hyland V.J., Robinson B.G., Frilling A., Verellen-Dumoulin C., Safar A., et al. Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene. Hum Mol Genet 1994, 3:2163-2167.
20. Pelet A., Geneste O., Edery P., Pasini A., Chappuis S., Attié T., Munnich A., Lenoir G., Lyonnet S., Billaud M. Various mechanisms cause RET-mediated signaling defects in Hirschsprung's disease. J Clin Invest 1998, 101:1415-1423.
21. Bordeaux M.C., Forcet C., Granger L., Corset V., Bidaud C., Billaud M., Bredesen D.E., Edery P., Mehlen P. The RET proto-oncogene induces apoptosis: a novel mechanism for Hirschsprung disease. EMBO J 2000, 19:4056-4063.
22. Gimm O., Neuberg D.S., Marsh D.J., Dahia P.L.M., Hoang-Vu C., Raue F., Hinze R., Dralle H., Eng C. Over-representation of a germline RET sequence variant in patients with sporadic medullary thyroid carcinoma and somatic RET codon 918 mutation. Oncogene 1999, 18:1369-1370.
23. Borrego S., Wright F.A., Fernández R.M., Williams N., López-Alonso M., Davuluri R., Antiñolo G., Eng C. A founding locus within the RET proto-oncogene may account for the majority of apparently sporadic Hirschsprung disease and a subset of sporadic medullary thyroid cancer. Am J Hum Genet 2003, 72:88-100.
24. Cebrian A., Lesueur F., Martin S., Leyland J., Ahmed S., Luccanni C., Smith P.L., Luben R., Whittaker J., Pharoah P.D., et al. Polymorphisms in the initiators of RET signaling pathway and susceptibility to sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 2005, 90:6268-6274.
25. Borrego S., Saez M.E., Ruiz A., Gimm O., Lopez-Alonso M., Antiñolo G., Eng C. Specific polymorphisms in the RET proto-oncogene are over-represented in individuals with Hirschsprung disease and may represent loci modifying phenotypic expression. J Med Genet 1999, 36:771-774.
26. Borrego S., Saez M.E., Ruiz A., Gimm O., Gao X., Lopez-Alonso M., Hernandez A., Wright F.A., Antiñolo G., Eng C. RET genotypes comprising specific haplotypes of polymorphic variants predispose to isolated Hirschsprung disease. J Med Genet 2000, 37:572-578.
27. Fernandez R.M., Robledo M., Antinolo G., Pecina A., Ruiz-Llorente S., Eng C., Borrego S. The RET IVS1-126G>T variant is strongly associated with the development of sporadic medullary thyroid cancer. Thyroid 2004, 14:329-331.
28. Fernandez R.M., Boru G., Peciña A., Jones K., Lopez-Alonso M., Antiñolo G., Borrego S., Eng C. Ancestral RET haplotype associated with Hirschsprung disease shows linkage disequilibrium breakpoint at -1249. J Med Genet 2005, 42:322-327.
29. Ruiz-Ferrer M., Fernandez R.M., Aniñolo G., Lopez-Alonso M., Eng C., Borrego S. A complex additive model of inheritance for Hirschsprung disease is supported by both RET mutations and predisposing RET haplotypes. Genet Med 2006, 8:704-710.
30. Gimm O., Dziema H., Brown J.L., Hoang-Vu C., Hinze R., Dralle H., Mulligan L.M., Eng C. Over-representation of a germline variant in the gene encoding RET co-receptor GFRa-1 but not GFRa-2 or GFRa-3 in cases with sporadic medullary thyroid carcinoma. Oncogene 2001, 20:2161-2170.
31. Hemminki K., Eng C., Chen B. Familial risks for non-medullary thyroid cancer. J Clin Endocrinol Metab 2005, 90:5747-5753.
32. Hodgson S.V., Foulkes W.D., Eng C., Maher E.R. Practical Handbook of Human Cancer Genetics 2006, Cambridge University Press, Cambridge. 3rd edn.
33. Goto M., Miller R.W., Ishikawa Y., Sugano H. Excess of rare cancers in Werner syndrome (adult progeria). Cancer Epidemiol Biomark Prevent 1996, 5:239-246.
34. Stratakis C.A., Kirschner L.S., Carney J.A. Clinical and molecular features of the Carney complex diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab 2001, 86:4041-4046.
35. Neumann H.P.H., Pawlu C., Peçzkowska M., Bausch B., McWhinney S.R., Muresan M., Buchta M., Franke G., Klisch J., Bley T., et al. Distinct clinical features characterize paraganglioma syndromes associated with SDHB and SDHD mutations. J Am Med Assoc 2004, 292:943-951.
36. Vanharanta S., Virta S.R., Lehtonen R., Järvinen H., Mecklin J.-P., Juhola M., Herva R., Nupponen N.N., Aaltonen L.A., Buchta M., et al. Early onset renal cell carcinoma as novel extra-paraganglial component of SDHB-associated heritable paraganglioma. Am J Hum Genet 2004, 74:153-159.
37. Eng C. Familial papillary thyroid cancer-many syndromes, too many genes?. J Clin Endocrinol Metab 2000, 85:1755-1757.
38. Gudmundsson J., Sulem P., Gudbjartsson D.F., Jonasson J.G., Sigurdsson A., Bergthorsson J.T., He H., Blondai T., Geller F., Jakobsdottir M., et al. Common variants on 9q22.33 and 14q13.3 predisposes to thyroid cancer in European populations. Nature 2009, 41:460-464.
39. Weber F., Tereski R.E., Broelsch C.E., Frilling A., Eng C. A limited set of human microRNA's are deregulated in follicular thyroid carcinoma. J Clin Endocrinol Metab 2006, 91:3584-3591.
40. Jadziewski K., Murray E.L., Fransilla K., Jarzab B., Schoenberg D.R., delaChapelle A. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci U S A 2008, 105:7269-7274.
41. Jadziewski K., Liyanarachchi S., Panchucki J., Ringel M.D., Jarzab B., delaChapelle A. Polymorphic mature micro-RNAs from passenger strand of miR-146a contribute to thyroid cancer. Proc Natl Acad Sci U S A 2009, 106:1502-1505.
42. Vierimaa O., Georgitsi M., Lehtonen R., Vahteristo P., Kokko A., Raitila A., Tuppurainen K., Ebeling T.M., Salmela P.I., Paschke R., et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 2006, 312:1228-1230.
43. Khoo S.K., Pendek R., Nicholov R., Luccio-Camelo D.C., Newton T.L., Massie A., Petillo D., Menon J., Cameron D., Teh B.T., Chan S.P. Genome-wide scan identifies modifier loci acromegalic phenotypes for isolated familial somatotropinoma. Endocr Relat Cancer 2009, 16:1057-1063.
44. Kirschner L.S., Carney J.A., Pack S., Taymans S.E., Giatzakis C., Cho Y.S., Cho-Chung Y.S., Stratakis C.A. Mutations of the gene encoding the protein kinase A type 1-alpha regulatory subunit in patients with Carney complex. Nat Genet 2000, 26:89-92.
45. Horvath A., Boikos S., Glatzakis C., Robinson-White A., Groussin L., Griffin K.L., Stein E., Levine E., Delimpasi G., Hsiao H.P., et al. A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A4) in individuals with adrenocortical hyperplasia. Nat Genet 2006, 38:794-800.
46. Horvath A., Mericq V., Stratakis C.A. Mutation in PDE8B in adrenal hyperplasia. N Engl J Med 2008, 358:750-752.
47. Horvath A., Korde L., Greene M.H., Libe R., Osorio P., Faucz F.R., Raffin-Sanson M.L., Tsang K.M., Krori-Herishanu L., Patronas Y., et al. Functional phosphodiesterase 11A mutations modify the risk of familial and bilateral testicular germ cell tumours. Cancer Res 2009, 69:5301-5306.
48. Edelman E., Eng C. A practical guide to the interpretation and clinical application of personal genomic screening. Br Med J 2009, 339:b4253.
49. Khoury M.J., McBride C.M., Schully S.D., Ioannidis J.P., Feero W.G., Janssens A.C., Gwimm M., Simons-Morton D.G., Bernhardt J.M., Cargill M., et al. The scientific foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genet Med 2009, 11:559-567.
50. Porter M.E., Teisberg: E.O. Redefining Health Care: Creating Value-Based Competition on Results 2006, Harvard Business School Press, Boston.